EII.F Overview
Upcoming Projects (EII.F)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (EII.F)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (EII.F)
-
Eisai Alzheimer's Abeta BAN2401 Phase I/II data expected in mid 2017
Tickers: BIIB, EII.F
Occurred on: Dec 21, 2017 -
FDA accepts priority review sNDA for Eisai's anticancer agent Lenvatinib seeking approval for renal cell carcinoma; PDUFA May 16 2016
Ticker: EII.F
Occurred on: May 16, 2016 -
Phase III trial results of Eisai's anticancer agent Halaven in soft tissue sarcoma published in The Lancet
Ticker: EII.F
Occurred on: Feb 12, 2016 -
US FDA approves Eisai's anticancer agent Halaven (eribulin mesylate) for the treatment of advanced liposarcoma
Ticker: EII.F
Occurred on: Jan 29, 2016 -
Eisai has entered the generic pharmaceutical business in China through the acquisition of Liaoning TianYi Biological
Ticker: EII.F
Occurred on: Dec 28, 2015
Strategic Initiatives (EII.F)
-
Eisai acquires exclusive license from Huya Bioscience to develop and market HDAC inhibitor HBI-8000 in Japan and other Asian countries
Ticker: EII.F
Announcement Date: Feb 01, 2016
